Walker, Ulrich A; Courvoisier, Delphine S; Dudler, Jean; Aeberli, Daniel; von Kempis, Johannes; Scherer, Almut; Finckh, Axel; on behalf of the, Swiss Clinical Quality Management Programme in Rheumatic Disease (2011). Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion. Rheumatology, 50(1), pp. 243-244. Oxford: Oxford University Press 10.1093/rheumatology/keq258
|
Text
keq258.pdf - Published Version Available under License Publisher holds Copyright. Download (37kB) | Preview |
Sir, anti TNF-α agents (aTNFs) are the most commonly prescribed biological agents in RA. More recently abatacept (ABA), a T-cell costimulation modulator, and rituximab (RTX), a monoclonal antibody directed against CD20, have become available. Observational studies suggest that switching to a new drug class may be more effective in uncontrolled RA than switching to a class of biologics to which the patient had unsuccessfully been exposed [1]. Information about the efficacy and safety of cycling strategies through third-line biologics is lacking. This study aimed to analyse the effectiveness and safety of switching patients to ABA as the third biological class after failure of aTNF plus RTX.
The Swiss Clinical Quality Management (SCQM) programme for RA is a longitudinal population-based cohort, which has been approved by the local ethics committees of all participating centres [2]. For this analysis, we collected all the …
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology |
UniBE Contributor: |
Aeberli, Daniel |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1462-0324 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:10 |
Last Modified: |
05 Dec 2022 14:01 |
Publisher DOI: |
10.1093/rheumatology/keq258 |
PubMed ID: |
20716674 |
Web of Science ID: |
000285193500033 |
BORIS DOI: |
10.7892/boris.1640 |
URI: |
https://boris.unibe.ch/id/eprint/1640 (FactScience: 203422) |
Actions (login required)
 |
Edit item |